Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $17.1667.

A number of analysts have recently weighed in on the stock. HC Wainwright upped their target price on shares of Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock. Piper Sandler reissued an “overweight” rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Finally, Rodman & Renshaw raised shares of Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors have recently bought and sold shares of KPTI. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics during the 2nd quarter valued at about $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics during the 2nd quarter valued at about $56,000. Hsbc Holdings PLC purchased a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at about $66,000. Corient Private Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $74,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $95,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Trading Down 0.1%

Shares of Karyopharm Therapeutics stock opened at $9.10 on Friday. The company’s fifty day simple moving average is $7.86 and its two-hundred day simple moving average is $7.43. The company has a market cap of $206.21 million, a P/E ratio of -0.60 and a beta of 0.80. Karyopharm Therapeutics has a 12-month low of $3.65 and a 12-month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to analysts’ expectations of $31.40 million. Analysts predict that Karyopharm Therapeutics will post -3.52 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.